In this study, the most resistance is against trimethoprim-sulfamethoxazole antibiotics (52.6%) and the highest rate of sensitivity is related to nitrofurantoin (81%) which is consistent with the study of Mukherjee et al. and similar to the antimicrobial resistance of
E. coli in the year 2018. In the Mukherjee study, the highest rate of sensitivity was related to nitrofurantoin (72.5%) (
13). Resistance to antibiotics, among pathogenic bacteria, is a topic that has been considered today as a global problem.
E. coli is one of the most important pathogens which shows resistance against common antibiotics (
14,
15). In the study carried out in India by Sharma et al. (
16) in order to evaluate the antimicrobial resistance of
E. coli during 2012 - 2014, it was found that the highest rate of bacteria isolated from patients was
E. coli with (67.66%). In this research,
E. coli has shown the most rate of sensitivity to nitrofurantoin. Reduced sensitivity to nitrofurantoin is consonant with a recent study from 1.36 % in 2016 to 15.18 % in 2018.
The results of Barour el al. (
17), showed that among the 198
E. coli strains, elevated resistance rates were related to ampicillin (59.09%) and tetracycline (43.43%), and low resistance rates were observed for nalidixic acid (8.08%), ciprofloxacin (7.07%), kanamycin (6.56%), cefotaxime (4.54%), chloramphenicol (4.04%), nitrofurantoin (2.52%), cefoxitin (2.02%), gentamycin (1.01%), and however did not find colistin resistance isolates. Their results were accordance with our finding.
Sharma et al. (
16) indicated that the rate of resistance of 3rd generation cephalosporins had been accompanied by an increase of 15% in the years of 2012 - 2014. In our study, we have used 3rd generation cephalosporins such as cefixime and ceftriaxone, which increased the resistance of both antibiotics over the years have been reported. The rate of the resistance of
E. coli against trimethoprim-sulfamethoxazole in the new study has risen over the three years, and it was nearly 100 percent, while in our study the rate of resistance had been 52.6% in 2016, 53.6% in 2017 and 40.3% in 2018. Similar to our results, a study from Iran showed that among 100
E. coli isolates collected from different clinical specimens, the maximum resistance was related to amoxicillin (96%), ceftriaxone (78%), cefazolin (76%), co-trimoxazole (70%), cefotaxime (67%) and ceftazidime (66%) (
18). The observation of drug resistance among
E. coli strains in this study is alarming, and this could be attributed to the indiscriminate and extensive use of antibiotics, particularly beta-lactam antibiotics.
In another study performed by Sanchez et al. (
19) in order to evaluate the
E. coli antimicrobial resistance in 2002 - 2010, it turned out that ciprofloxacin resistance increased from 3.40 to 17.160 and trimethoprim-sulfamethoxazole resistance had increased from 17.9% to 24.26%. The ascending of resistance increase in the Sanchez study is consistent with the recent study. The incidence rate of resistance, an increasing trend in ceftriaxone, ciprofloxacin, nalidixic acid and cefixime and downtrend in nitrofurantoin, gentamicin, amikacin, and trimethoprim-sulfamethoxazole indicated that the resistance is contradictory with trimethoprim-sulfamethoxazole with the Sanchez study. In the study published in 2008 by Dallal et al. (
20) of the 188 examined
E. coli strains , the highest antimicrobial resistance respectively is related to cotrimoxazole (72%), nalidixic acid (69%), ciprofloxacin (99%) and gentamicin 31% which correspond with the rate of resistance in the current study that includes trimethoprim-sulfamethoxazole (52.6%), nalidixic acid (49.9%), ciprofloxacin (29.8%) and gentamicin (17.7%). But the rate of resistance in that was found in India in 2014 with the title: “
E. coli antimicrobial resistance”, the highest resistance included ceftriaxone (71.4%), cotrimoxazole (64.2%), and the highest sensitivity is for amikacin (82.6%), nitrofurantoin (78.2%). The rate of ceftriaxone resistance contradicts with the recent study. Somashekara et al. (
21) during a study in 2011 found that the highest rate of
E. coli microbial resistance is related to nalidixic acid (78.8%), trimethoprim-sulfamethoxazole (75.2%), ciprofloxacin (57.8%) and amikacin (26%) antibiotics while in our study highest rate of resistance was firstly related to trimethoprim-sulfamethoxazole (52.6%) and after that nalidixic acid with 49.4%. Also through this study, the significant relationship (P value < 0.05) was observed between the resistance of cefixime, ciprofloxacin, nalidixic acid, ceftriaxone, gentamicin and amikacin antibiotics and different years (91 - 93). Therefore with increasing age, we have increase in the resistance. In this study, the relationship between antibiotic resistance and different age groups (1 - 100) was studied. According to the statistical analyses, a significant relationship was observed between the resistance of cefixime, ciprofloxacin, ceftriaxone, gentamicin and nalidixic acid antibiotics and the age of people, such that the resistance of cefixime, ciprofloxacin, ceftriaxone, gentamicin, and antibiotics was highest in the age group of 81 - 90 and resistance to nalidixic acid antibiotic in the age group of 91 - 100 has 100 percent resistant.
5.1. Conclusions
The results of this study showed that antibiotic resistance patterns exist in different regions, and the rate of this resistance is increasing continuously. This pattern is different from region to region due to the geographical disparity, district hygiene level, and the rate of arbitrary administration of antibiotics in different areas. The emersion of resistance to new antibiotics is a matter to be taken seriously, therefore, continuous evaluation of bacteriology, and correct and rapid diagnosis of antibiotic resistance, followed by identifying the correct line of treatment can make a significant contribution to preventing treatment failure, performing quicker treatment and saving time and cost to the patients. By recognition of resistance patterns in each area, we can prevent the resistant gene spread, and help physicians to cure patients more precisely.